Compare BIO-TECHNE Corp (TECH) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Total Stock Market Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Vanguard Total Stock Market Index Fund ETF trades at $369.5. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals.
| TECH | VTI | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | — |
52-Week High | $72.12 | $374.36 |
52-Week Low | $43.31 | $305.74 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
VTI trades at $366.25, down 0.21% on the day, with a bearish technical signal from moving averages. The ETF provides diversified exposure to the entire U.S. stock market with over 3,500 holdings and an ultra-low 0.03% expense ratio. Recent news highlights its appeal for long-term investors seeking broad market coverage and historical resilience during market downturns.
The outlook remains positive for buy-and-hold investors given VTI's diversification benefits and cost efficiency. Key risks include broader market volatility and sector concentration in technology. Wall Street sentiment is generally favorable for long-term wealth building, though short-term technical indicators suggest caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
